Inconsistent dosing of anti-tuberculosis drugs in Taipei, Taiwan

International Journal of Tuberculosis and Lung Disease

Volumn 14, Issue 7, 2010, Pages 878-883

  Chiang, Chen Yuan ^a,b   Bai, K J ^b   Lee, C N ^b   Enarson, D A ^a   Suo, J ^c   Luh, K T ^c  

^a INTERNATIONAL UNION AGAINST TUBERCULOSIS AND LUNG DISEASE   (France)

^b TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^c National Tuberculosis Association   (Taiwan)

Author keywords

Dosage; Fixed dose combination; Isoniazid; Rifampicin

Indexed keywords

CIPROFLOXACIN; ETHAMBUTOL; ISONIAZID; ISONIAZID PLUS RIFAMPICIN; OFLOXACIN; PYRAZINAMIDE; RIFAMPICIN; STREPTOMYCIN; DRUG COMBINATION; TUBERCULOSTATIC AGENT;

ACUTE HEPATITIS; ACUTE KIDNEY FAILURE; ADULT; AGED; ARTICLE; BODY WEIGHT; CHRONIC HEPATITIS; CHRONIC KIDNEY FAILURE; COMORBIDITY; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG MEGADOSE; EXTRAPULMONARY TUBERCULOSIS; FEMALE; HUMAN; INFORMATION PROCESSING; LIVER CIRRHOSIS; LOW DRUG DOSE; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MEDICAL AUDIT; MEDICAL PRACTICE; MEDICAL RECORD REVIEW; PRESCRIPTION; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; SINGLE DRUG DOSE; TAIWAN; ADOLESCENT; CLINICAL PRACTICE; DOSE RESPONSE; DRUG COMBINATION; MIDDLE AGED; ORGANIZATION AND MANAGEMENT; PUBLIC HEALTH; STANDARDS; TUBERCULOSIS; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTITUBERCULAR AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMBINATIONS; FEMALE; HUMANS; ISONIAZID; MALE; MEDICAL AUDIT; MIDDLE AGED; NATIONAL HEALTH PROGRAMS; PHYSICIAN'S PRACTICE PATTERNS; RIFAMPIN; TAIWAN; TUBERCULOSIS; YOUNG ADULT;

EID: 77953627690     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Enarson D A, Rieder H L, Arnadottir T, Trébucq A. Management of tuberculosis. A guide for low-income countries. 5th ed. Paris, France: International Union Against Tuberculosis and Lung Disease, 2000.
2. World Health Organization. Treatment of tuberculosis: guidelines for national programmes. 3rd ed. WHO/CDS/TB/2003. 313:1-108. Geneva, Switzerland: WHO, 2003.
3. Taiwan Centers for Disease Control, Department of Health. Taiwan guideline on tuberculosis diagnosis and treatment. 2nd ed. Taipei, Taiwan: Department of Health, 2006.
4. Diop A H, Gakiria G, Pande S B, Malla P, Rieder H L. Dosages of anti-tuberculosis medications in the national tuberculosis programs of Kenya, Nepal and Senegal. Int J Tuberc Lung Dis 2002; 6: 215-221. (Pubitemid 34270099)
5. Harries A D, Gausi F, Salaniponi F M. Prescriptions and dosages of anti-tuberculosis drugs in the National Tuberculosis Control Programme of Malawi. Int J Tuberc Lung Dis 2004; 8: 724-729. (Pubitemid 38747148)
6. Chiang C-Y, Luh K-T, Enarson D A, Yang S-L, Wu Y-C, Lin T-P. Accuracy of classification of notified tuberculosis cases in Taiwan. Int J Tuberc Lung Dis 2007; 11: 876-881.
7. Chiang C-Y, Enarson D A, Bai K-J, et al. Factors associated with a clinician's decision to stop anti-tuberculosis treatment before completion. Int J Tuberc Lung Dis 2008; 12: 441-446.
8. International Union Against Tuberculosis and Lung Disease. Anti-tuberculosis regimens of chemotherapy. Recommendations from the Committee on Treatment of the International Union Against Tuberculosis and Lung Disease. Bull Int Union Tuberc Lung Dis 1988; 63 (2): 60-64.
9. Hosmer D W, Lemeshow S. The multinomial logistic regression model. In: Hosmer D W, Lemeshow S, eds. Applied logistic regression. 2nd ed. New York, NY, USA: John Wiley & Sons, 2000: pp 260-287.
10. Chiang C-Y, Lee J-J, Yu M-C, Bai K-J, Lin T-P, Luh K-T. Tuberculosis-related deaths without treatment. Int J Tuberc Lung Dis 2009; 13: 1563-1565.
11. Mitchison D A. How drug resistance emerges as a result of poor compliance during short course chemotherapy of tuberculosis. Int J Tuberc Lung Dis 1998; 2: 10-15.
12. Thompson N P, Caplin M E, Hamilton M I, et al. Anti-tuberculosis medications and the liver: dangers and recommendations in management. Eur Respir J 1995; 8: 1384-1388.
13. Saukkonen J J, Cohn D L, Jasmer R M, et al. An official ATS statement: hepatotoxicity of anti-tuberculosis therapy. Am J Respir Crit Care Med 2006; 174: 935-952.
14. Rieder H L. Interventions for tuberculosis control and elimination. Paris, France: International Union Against Tuberculosis and Lung Disease, 2002.
15. Chiang C-Y, Bai K-J, Lee C-N, Enarson D A, Suo J, Luh K-T. Inconsistent dosing of rifampin in the treatment of tuberculosis in Taipei. Thoracic Med 2007; 22 (Suppl): 7.
16. Chan P-C, Hsu C-B, Lin H-C, et al. The deviation from standardized treatment regimen in 108 randomly selected smear-positive tuberculosis patients. Taiwan Epidemiol Bull 2008; 24: 254-263.
17. Li Y-P, Chan P-C, Wang K-F, Yang C-H, Kuo H-S. Introduction of reducing reimbursement from NHI to improve the inadequate regimen for TB control. Int J Tuberc Lung Dis 2009; 13 (Suppl): S107.
18. Chan P-C, Hsu C-B, Wang K-F, et al. The impact of national endorsement of standardized regimens on TB care. Int J Tuberc Lung Dis 2009; 13 (Suppl): S207.